论文部分内容阅读
恶性胸腔积液是由于胸膜原发性肿瘤和肺部或全身恶性肿瘤转移至胸膜后出现的常见并发症,如果不能较好控制,可产生胸水压迫症状及呼吸困难,更重要的是患者将很快出现恶病质,以至不能承受全身化疗和放疗,失去治疗机会,缩短存活期.因此,恶性胸腔积液的理想控制在临床治疗上有着重要意义.本文旨在探讨IL-2治疗恶性胸腔积液的临床效果及毒副反应.探讨治疗恶性胸腔积液的新方法.(1)临床资料:本组患者共68例,其中男性47例,女性21例,年龄28～69岁,中位年龄为54.6岁,原发性肺腺癌18例、肺小细胞未分化癌20例、肺鳞癌14例、食道癌肺转移14例、乳腺癌肺转移2例.本组病例均是经病理确诊的晚期肿瘤患者,68例患
Malignant pleural effusions are the common complications that occur after pleural primary tumors and lung or systemic malignancies metastasize to the pleura. If they are not well controlled, they can cause pleural effusion and difficulty breathing. More importantly, patients will Rapid cachexia, can not afford systemic chemotherapy and radiotherapy, loss of treatment opportunities, shorten the survival period. Therefore, the ideal control of malignant pleural effusion in clinical treatment is of great significance. This article aims to explore the IL-2 treatment of malignant pleural effusion Clinical effects and side effects. To explore new methods for the treatment of malignant pleural effusion. (1) Clinical data: 68 patients in this group, including 47 males and 21 females, aged 28 to 69 years, median age 54.6 At the age of 18 years, there were 18 cases of primary lung adenocarcinoma, 20 cases of lung small cell undifferentiated carcinoma, 14 cases of squamous cell carcinoma of the lung, 14 cases of esophageal cancer, 15 cases of lung metastasis, and 2 cases of lung metastasis of breast cancer. These cases were diagnosed by advanced pathology. In patients with cancer, 68 patients suffer from